Clinical Trial to Treat Rare Skin Disorder With siRNA Technology
U.S. Newswire, January, 2008
To: NATIONAL EDITORS
Contact: Mary Schwartz, Pachyonychia Project Director, 1-877 628- 7300, mary.schwartz@pachyonychia.org
SALT LAKE CITY, Jan. 17 /PRNewswire-USNewswire/ --PC Project, a public charity, announced that a Phase 1b clinical trial began today for treatment of pachyonychia congenita (PC) with a short interfering RNA (siRNA)-based therapeutic. PC is a dominant genetic disorder resulting from mutations in genes that encode keratins, which give structural integrity to skin cells.
Dr. Sancy Leachman, a University of Utah Dermatologist, is leading the study using a newly developed siRNA called TD101. This new drug has received the orphan drug designation (drug for rare diseases) by the US FDA under the Orphan Drug Act and was developed by TransDerm...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Getting the global view: Nestle, led by Peter Brabeck-Letmathe, climbs to the #1 spot in this year's Best Companies for Leaders
